ArticleBMC cardiovascular disorders2025
The Advanced Lung Cancer Inflammation Index and Mortality in Patients with Cardiovascular-Kidney Metabolic Syndrome: Insights from NHANES.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Cardiovascular-kidney-metabolic syndrome: a comprehensive review of pathophysiology, epidemiology, diagnosis, and management.Cardiovascular diabetology · 2026Review
- Prognostic significance of the advanced lung cancer inflammation index for long-term mortality in patients with acute myocardial infarction and diabetes.Frontiers in endocrinology · 2026Article
- The association of the advanced lung cancer inflammation index with the risk ofFrontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe advanced lung cancer inflammation index (ALI) is a marker of inflammation, yet its prognostic value in cardiovascular-kidney-metabolic (CKM) syndrome has not been explored. This study examines the relationship between ALI and mortality risk in patients with CKM.
methodsWe analyzed data from 14,301 CKM patients in the National Health and Nutrition Examination Survey (1999–2018). We assessed ALI tertiles (Tertile 1–Tertile 3) using Cox regression, restricted cubic splines, Kaplan-Meier survival curves, and receiver operating characteristic curves. We also performed sensitivity analyses to confirm the robustness of our results.
resultsIn a cohort of 14, 301 patients with CKM syndrome, 2,418 deaths from all causes, 765 cardio-cerebrovascular deaths, and 590 cancer-related deaths were recorded. After adjusting for potential confounders, the weighted multivariate Cox model showed that higher ALI was significantly associated with a reduced risk of all-cause and cardio-cerebrovascular mortality (all P < 0.001). However, a correlation between ALI scores and reduced cancer mortality was only observed in Tertile 2 for cancer mortality (P= 0.01). Smooth curve fitting revealed nonlinear correlations between ALI and mortality across CKM stages 0–4, 0–3, and 4 (log-likelihood ratio test P < 0.001). Stratified analyses identified significant interactions between age (P for interaction = 0.03) and smoking status (P for interaction < 0.001) with all-cause mortality, and between chronic kidney disease prognosis and cancer mortality (P for interaction = 0.03) in CKM syndrome patients. Receiver operating characteristic curves confirmed that ALI is a strong predictor of both short- and long-term all-cause, cardio-cerebrovascular, and cancer mortality.
conclusionOur study shows that ALI is negatively correlated with all-cause, cardio-cerebrovascular, and cancer mortality within a certain range in patients with CKM syndrome. ALI is an effective prognostic predictor of mortality risk in individuals with CKM syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.